• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾小球滤过率是 B 大细胞淋巴瘤患者的独立预后因素。

Glomerular filtration rate is an independent prognostic factor in patients with B-large cell lymphoma.

机构信息

Division of Nephrology, Department of Internal Medicine, University Hospital Centre Zagreb.

Medical School, University of Zagreb.

出版信息

Medicine (Baltimore). 2023 May 19;102(20):e33675. doi: 10.1097/MD.0000000000033675.

DOI:10.1097/MD.0000000000033675
PMID:37335743
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10194734/
Abstract

Chronic kidney dysfunction is associated with increased mortality in multiple cancer types. Preliminary evidence suggests the same to be true for B-large cell lymphomas (B-LCL). To analyze the relationship of glomerular filtration rate (GFR) and outcome of B-LCL in detail we collected data on outcomes of 285 consecutive patients with newly diagnosed B-LCL treated at our institution with standard rituximab-containing regimens who did not have preexisting kidney disease or urinary tract obstruction at presentation. Median age was 59, range 18 to 87, 145 were male and 140 females. Forty-four had GFR < 60 mL/min, 123 had 60 to 90 mL/min, and 118 > 90 mL/min. Median follow-up of surviving patients was 49 months and estimated 3-year survival 76%. In univariate analysis age (P < .001), GFR (P = .014), stage (P < .001), performance status (P = .044), chemotherapy regimen (P < .01), and international prognostic index (IPI) (P < .001) were statistically significant prognostic factors. In multivariate analysis, age and GFR remained the only independent prognostic factors. Subtracting 1 from the IPI score of patients who had GFR > 90 mL/min and IPI > 1 resulted in a prognostic index that divides patients into 3 prognostic groups (low risk = 0-1, intermediate risk = 2-3 and high risk = 4-5) with an acceptable patient distribution frequency (38%, 39%, and 23%, respectively) and improved statistical significance and separation in comparison to IPI (5-year survival rates of 92%, 74%, and 42%, respectively). GFR is an important independent prognostic factor for B-LCL that should be taken into account in clinical decision making and data analysis and probably be incorporated in prognostic indices.

摘要

慢性肾功能障碍与多种癌症类型的死亡率升高有关。初步证据表明,B 大细胞淋巴瘤(B-LCL)也是如此。为了详细分析肾小球滤过率(GFR)与 B-LCL 结局之间的关系,我们收集了在我院接受标准含利妥昔单抗方案治疗的 285 例新诊断为 B-LCL 的连续患者的结局数据,这些患者在就诊时没有预先存在的肾脏疾病或尿路梗阻。中位年龄为 59 岁,范围为 18 至 87 岁,145 例为男性,140 例为女性。44 例患者的 GFR<60mL/min,123 例患者的 GFR 为 60 至 90mL/min,118 例患者的 GFR>90mL/min。存活患者的中位随访时间为 49 个月,估计 3 年生存率为 76%。在单因素分析中,年龄(P<0.001)、GFR(P=0.014)、分期(P<0.001)、体能状态(P=0.044)、化疗方案(P<0.01)和国际预后指数(IPI)(P<0.001)是统计学上显著的预后因素。在多因素分析中,年龄和 GFR 仍然是唯一的独立预后因素。将 GFR>90mL/min 且 IPI>1 的患者的 IPI 评分减去 1,得到一个预后指数,将患者分为 3 个预后组(低危组=0-1,中危组=2-3,高危组=4-5),患者分布频率可接受(分别为 38%、39%和 23%),与 IPI 相比,统计学意义和分离度均有所提高(5 年生存率分别为 92%、74%和 42%)。GFR 是 B-LCL 的一个重要独立预后因素,在临床决策和数据分析中应予以考虑,并可能被纳入预后指数。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02d8/10194734/d0ae89e31bc3/medi-102-e33675-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02d8/10194734/cd3f2ebd6184/medi-102-e33675-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02d8/10194734/a6bd76e5b19a/medi-102-e33675-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02d8/10194734/d0ae89e31bc3/medi-102-e33675-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02d8/10194734/cd3f2ebd6184/medi-102-e33675-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02d8/10194734/a6bd76e5b19a/medi-102-e33675-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02d8/10194734/d0ae89e31bc3/medi-102-e33675-g003.jpg

相似文献

1
Glomerular filtration rate is an independent prognostic factor in patients with B-large cell lymphoma.肾小球滤过率是 B 大细胞淋巴瘤患者的独立预后因素。
Medicine (Baltimore). 2023 May 19;102(20):e33675. doi: 10.1097/MD.0000000000033675.
2
Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.弥漫性大B细胞非霍奇金淋巴瘤的临床预后因素:一项回顾性研究。
J Egypt Natl Canc Inst. 2011 Mar;23(1):17-24. doi: 10.1016/j.jnci.2011.07.003. Epub 2011 Sep 8.
3
[Clinical characteristics and prognostic features of 63 HIV-associated diffuse large B-cell lymphoma: a single-center real-world study in China].63例HIV相关弥漫性大B细胞淋巴瘤的临床特征及预后因素:中国一项单中心真实世界研究
Zhonghua Xue Ye Xue Za Zhi. 2022 Mar 14;43(3):203-208. doi: 10.3760/cma.j.issn.0253-2727.2022.03.004.
4
[Efficacy of surgery and rituximab in primary gastric diffuse large B-cell lymphoma].手术与利妥昔单抗治疗原发性胃弥漫性大B细胞淋巴瘤的疗效
Zhonghua Xue Ye Xue Za Zhi. 2016 Jul;37(7):602-6. doi: 10.3760/cma.j.issn.0253-2727.2016.07.012.
5
[Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].[比较老年弥漫性大B细胞淋巴瘤不同一线治疗的疗效及预后]
Zhonghua Zhong Liu Za Zhi. 2020 Mar 23;42(3):234-241. doi: 10.3760/cma.j.cn112152-20190705-00413.
6
Treatment Strategies and Prognostic Factors of Primary Gastric Diffuse Large B Cell Lymphoma: A Retrospective Multicenter Study of 272 Cases from the China Lymphoma Patient Registry.原发性胃弥漫大 B 细胞淋巴瘤的治疗策略和预后因素:来自中国淋巴瘤患者登记处的 272 例回顾性多中心研究。
Int J Med Sci. 2019 Jun 10;16(7):1023-1031. doi: 10.7150/ijms.34175. eCollection 2019.
7
Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma.侵袭性非霍奇金淋巴瘤中免疫表型与国际预后指数的预后意义比较
Clin Lymphoma. 2003 Jun;4(1):52-5. doi: 10.3816/clm.2003.n.014.
8
The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.弥漫性大B细胞淋巴瘤的强化国际预后指数
Am J Med Sci. 2017 May;353(5):459-465. doi: 10.1016/j.amjms.2017.02.002. Epub 2017 Feb 8.
9
The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma.国际预后指数可作为指导针对人类免疫缺陷病毒相关系统性非霍奇金淋巴瘤患者进行治疗决策的依据。
Cancer. 1999 Dec 1;86(11):2391-7.
10
The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.R-IPI和NCCN-IPI预后风险评估工具时代预处理贫血的意义:一项针对弥漫性大B细胞淋巴瘤患者的双中心研究
Eur J Haematol. 2015 Dec;95(6):538-44. doi: 10.1111/ejh.12529. Epub 2015 Mar 26.

本文引用的文献

1
R-CHOEP14 in younger high-risk patients with large B cell lymphoma: an effective front-line regimen with cardiac toxicity: a real-life, single-center experience.R-CHOEP14 方案治疗年轻高危弥漫大 B 细胞淋巴瘤:具有心脏毒性的有效一线方案:真实世界、单中心经验。
Ann Hematol. 2021 Jun;100(6):1517-1524. doi: 10.1007/s00277-020-04353-3. Epub 2020 Nov 20.
2
Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma.米托蒽醌-美法仑预处理方案用于复发/难治性淋巴瘤的自体干细胞移植。
Turk J Med Sci. 2019 Aug 8;49(4):985-992. doi: 10.3906/sag-1809-36.
3
Prevalence and mortality of chronic kidney disease in lymphoma patients: A large retrospective cohort study.
淋巴瘤患者慢性肾脏病的患病率和死亡率:一项大型回顾性队列研究。
Medicine (Baltimore). 2018 Jan;97(2):e9615. doi: 10.1097/MD.0000000000009615.
4
Baseline renal function as a prognostic indicator in patients with newly diagnosed diffuse large B-cell lymphoma.基线肾功能作为新诊断弥漫性大B细胞淋巴瘤患者的预后指标。
Blood Res. 2016 Jun;51(2):113-21. doi: 10.5045/br.2016.51.2.113. Epub 2016 Jun 23.
5
Renal Function and All-Cause Mortality Risk Among Cancer Patients.癌症患者的肾功能与全因死亡风险
Medicine (Baltimore). 2016 May;95(20):e3728. doi: 10.1097/MD.0000000000003728.
6
CKD and the risk of incident cancer.慢性肾脏病与新发癌症风险
J Am Soc Nephrol. 2014 Oct;25(10):2327-34. doi: 10.1681/ASN.2013060604. Epub 2014 May 29.
7
Loss of renal function causes premature aging of the immune system.肾功能丧失导致免疫系统过早衰老。
Blood Purif. 2013;36(3-4):173-8. doi: 10.1159/000356084. Epub 2013 Dec 20.
8
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.自体移植作为侵袭性非霍奇金淋巴瘤的巩固治疗。
N Engl J Med. 2013 Oct 31;369(18):1681-90. doi: 10.1056/NEJMoa1301077.
9
Cancer and the kidney: individualizing dosage according to renal function.
Ann Oncol. 2013 Nov;24(11):2713-4. doi: 10.1093/annonc/mdt431.
10
Reduced estimated GFR and cancer mortality.估算肾小球滤过率降低与癌症死亡率。
Am J Kidney Dis. 2014 Jan;63(1):23-30. doi: 10.1053/j.ajkd.2013.07.008. Epub 2013 Aug 30.